FDA’s Opdivo Lung Cancer Approval

By João L. Carapinha

October 11, 2024

The FDA has approved a new treatment regimen using Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC), marking a significant advancement in cancer care. This approval paves the way for adult patients with resectable NSCLC to receive a combination of Opdivo and platinum-doublet chemotherapy as a neoadjuvant therapy, followed by surgery, and then adjuvant single-agent Opdivo. This targeted approach is for patients who do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) rearrangements.

Approval Details

The FDA has approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by surgery, and then adjuvant single-agent Opdivo for adult patients with resectable NSCLC. This approval specifically targets patients without EGFR or ALK rearrangements.

Clinical Trial

The approval is based on the results of the Phase III CheckMate-77T trial, a randomized, double-blind, multi-center study. The trial involved 461 patients and compared neoadjuvant Opdivo with platinum-doublet chemotherapy followed by surgery and adjuvant single-agent Opdivo against neoadjuvant platinum-doublet chemotherapy and placebo followed by surgery and adjuvant placebo.

Efficacy

Results demonstrated that the combination of Opdivo with chemotherapy significantly enhanced event-free survival (EFS) and pathologic complete response (pCR) compared to chemotherapy alone. Notably, the median EFS was not reached in the nivolumab arm, while it stood at 18.4 months in the chemotherapy arm (HR, 0.58; 95% CI, 0.43-0.78; P = 0.00025).

Safety

Adverse events (AEs) were comparable to those seen in previous clinical trials involving nivolumab and chemotherapy. A small portion of patients treated with nivolumab experienced delays in surgery or were unable to undergo the procedure due to AEs.

Clinical Implications

This FDA approval represents a critical step in addressing the treatment needs of patients requiring therapies before and after surgery to target micrometastasis, lower the risk of cancer recurrence, and enhance surgical success. This regimen holds promise for improved EFS and may lead to a pCR in one out of four patients.

Expanded Role of Opdivo

The FDA’s decision expands the role of Opdivo-based treatments, building upon prior approvals for neoadjuvant-only Opdivo plus chemotherapy for resectable NSCLC, as demonstrated in the CheckMate-816 trial. This reinforces Bristol Myers Squibb’s commitment to enhancing patient outcomes and broadening its thoracic portfolio in early-stage diseases, with Opdivo now playing a pivotal role in treatment protocols for resectable NSCLC.

Reference url

Recent Posts

health policy research
    

Future-Proofing Hospitals: Singapore’s Blueprint for Smarter Healthcare

🔍 How can hospitals stay ahead of aging populations, chronic diseases, and future crises?

In the article “Future-Proofing Hospitals: Singapore’s Blueprint for Smarter Healthcare”, based on a study published in Health Research Policy and Systems, Singapore’s largest hospital uses systems thinking to map complex healthcare dynamics. By leveraging causal loop diagrams, the study reveals four key principles—agility, innovative care models, sustainability, and systems thinking—to build resilient, patient-centric hospitals. These insights offer health executives and planners a practical roadmap to future-proof hospitals globally.

Want to explore how this approach can transform your healthcare strategy? Click to read the full article!

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

Pfizer conference insights
          

Pfizer Conference Insights: Analyzing Bourla’s Strategic Vision Amid Policy Changes

🩺 How will regulatory changes reshape the future of drug pricing and access?

Pfizer CEO Albert Bourla’s insights from the recent Goldman Sachs Healthcare Conference highlight significant shifts in the pharmaceutical landscape, particularly concerning the Most-Favored-Nation drug pricing executive order and its implications for innovation and affordability. Bourla emphasizes the need for a balanced approach to ensure that U.S. price reductions do not hinder global drug development.

Dive into the full article to explore how these dynamics could impact both patients and the industry.

#SyenzaNews #pharmaceuticals #healthcarepolicy

vaccine policy implications
           

RFK Jr.’s ACIP Overhaul: Examining Vaccine Policy Implications

🚨 Are we witnessing the dismantling of vaccine advocacy in the U.S.?

In a bold move, RFK Jr. has reshaped the Advisory Committee on Immunization Practices (ACIP), sparking debates about political influence in public health and potential risks to immunization progress. This article explores the implications of these changes, emphasizing the importance of nuanced perspectives in addressing vaccine policy and public trust.

Jump into the critical insights provided by Dr. Katelyn Jetelina and understand the broader repercussions of this overhaul on healthcare and immunization rates.

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.